



ORIGINAL ARTICLE

Understanding the measurement properties of the incremental shuttle walk test in patients with severe asthma

SALLY MAJD,^{1,2,3}  STACEY M. HEWITT,^{1,2} LINDSAY D. APPS,⁴ ANNA C. MURPHY,^{2,5,6} PETER BRADDING,^{2,3,5}
SALLY J. SINGH,^{1,2,3,5} RUTH H. GREEN^{2,3,5} AND RACHAEL A. EVANS^{1,2,3,5} 

¹Centre for Exercise Rehabilitation Science, Respiratory Sciences, Leicester, UK; ²Leicester Biomedical Research Centre (Respiratory), Glenfield Hospital, Leicester, UK; ³Department of Respiratory Science, University of Leicester, Leicester, UK; ⁴Division of Psychology, School of Applied Social Science, DeMontfort University, Leicester, UK; ⁵Department of Respiratory Medicine, Thoracic Surgery and Allergy, Glenfield Hospital, Leicester, UK; ⁶School of Pharmacy, DeMontfort University, Leicester, UK

ABSTRACT

Background and objective: We investigated the repeatability and validity of the incremental shuttle walk test (ISWT) distance compared to peak oxygen uptake ($\text{VO}_{2\text{pk}}$) during maximal incremental cycle ergometer (ICE) and treadmill (ITM) tests in adults with severe asthma.

Methods: Adults with severe asthma, Medical Research Council (MRC) dyspnoea ≥ 2 , were recruited from specialists caring for patients with severe asthma. All participants performed three ISWT (familiarization and two subsequent tests on the same day), an ICE and an ITM in a randomized order, on separate days, to intolerance with expiratory gas analysis.

Results: A total of 50 patients (32 females, mean (SD), age: 54 (13) years, forced expiratory volume in 1 s (FEV_1): 1.9 (0.8) L and body mass index (BMI): 32 (6) kg/m^2) completed all five tests. The mean (SD) ISWT distance for each test was 400 (156), 418 (142) and 438 (157) m ($P = 0.001$), respectively. There was a strong correlation between the ISWT distance with $\text{VO}_{2\text{pk}}$ derived from ITM ($r = 0.74$, $P < 0.001$) and ICE ($r = 0.75$, $P < 0.001$).

Conclusion: There was a small increase in the mean ISWT distance on sequential testing. In clinical practice, the coefficient of repeatability and heteroscedasticity need to be considered when assessing whether a true change has occurred within an individual patient. The ISWT has validity compared to $\text{VO}_{2\text{pk}}$ on both ICE and ITM, but they are not interchangeable.

Key words: cardiopulmonary exercise test, exercise capacity, incremental shuttle walk test, repeatability, severe asthma.

INTRODUCTION

Adults suffering from asthma may adopt a sedentary lifestyle due to fear of exacerbating asthma symptoms with exercise and are at risk of deconditioning.¹ Obesity

SUMMARY AT A GLANCE

The measurement properties of the incremental shuttle walk test (ISWT) are unknown in patients with severe asthma. The study results show ISWT can be used to assess exercise capacity in patients with severe asthma. However, the small increase in distance on repeated testing would need to be considered in non-randomized trials.

is a prevalent co-morbidity in asthma² associated with disease severity, worse asthma control and poor exercise habits.² Exertional dyspnoea in this group of patients is a complex and multifactorial issue, and may have different characteristics among patients with different levels of disease severity.³

The gold standard assessment of exercise capacity is the measurement of peak oxygen uptake ($\text{VO}_{2\text{pk}}$) during a maximal cardiopulmonary exercise test (CPET) with expired gas analysis. These tests are laboratory based requiring specialized equipment and trained operators. The incremental shuttle walk test (ISWT), a simple and inexpensive field test, has been shown to be valid and repeatable in other chronic lung diseases and has been used extensively to assess changes in exercise capacity after an intervention.^{4–7} However, the ISWT may have a ceiling effect due to the flat nature of the course, walking rather than running, and the changes in gait pattern with the turns at either end of the 10-m course which may be relevant for some patients with severe asthma who have a high body mass index (BMI).

We therefore aimed to assess both the short-term repeatability of the ISWT distance and the validity of the ISWT distance by comparing it to the $\text{VO}_{2\text{pk}}$ derived from maximal incremental treadmill (ITM) and cycle ergometer tests (ICE) in patients with severe asthma.

METHODS

Study design

This study was a prospective cross-sectional study approved by the National Research Ethics Service

Correspondence: Rachael A. Evans, Leicester Biomedical Research Centre (Respiratory), Glenfield Hospital, Groby Road, LE3 9QP Leicester, UK. Email: re66@leicester.ac.uk

Received 3 October 2018; invited to revise 17 November 2018; revised 13 January 2019; accepted 13 February 2019 (Associate Editor: Conroy Wong; Senior Editor: Fanny Ko).

Committee of the East Midlands (ref: 127552). The study timetable is shown in Figure 1. After providing written consent, participants performed a familiarization ISWT and subsequently two further ISWT (30 min apart) within 2 weeks. Participants were randomly assigned to perform either an ITM or ICE test first with one week between visits.

Participants

Participants were recruited from a population of patients attending severe asthma services with a multi-disciplinary team, at a tertiary referral centre Glenfield Hospital, Leicester, UK, for at least 6 months. All underwent thorough diagnostic assessment and an appropriate treatment strategy prior to recruitment. Patients were recruited if they were using high-dose therapies at step 4 or 5 of the previous SIGN/British Thoracic Society Guidelines 2014.⁸ Exclusion criteria included a diagnosis of a smoking-related chronic obstructive pulmonary disease (COPD), co-existing fixed airflow obstruction (forced expiratory volume in 1 s (FEV₁)/forced vital capacity (FVC) < 70%) with a smoking history of ≥10 pack-years and an inability to exercise due to significant musculoskeletal or neurological deficit and unstable cardiac disease (myocardial infarction within the last 3 months, unstable angina, heart failure or valvular disease). Specific exclusions relating to severe asthma were a severe exacerbation in the preceding month prior to entry to the programme, a hospital admission within the last 3 months and/or an admission involving intensive care and intubation within the last year.

Outcome measures

Incremental shuttle walk test

The modified ISWT is a 16-level test with an incremental acceleration every minute.⁷ The participant walks around two cones 9 m apart with a shuttle distance of 10 m.⁴ Standard encouragement was provided at the start of a new level and if they were unable to maintain the required speed whereby the test was terminated if the correct speed was not achieved by the subsequent 10-m shuttle.

Heart rate and oxygen saturation were measured continuously via portable pulse oximetry (Konica Minolta Pulsox-300i, Osaka, Japan). Blood pressure (BP) using sphygmomanometry, and perceived breathlessness and exertion using the Borg Scale,⁹ were

recorded before, every 2 min during and immediately at the end of the test. The main limiting symptom was recorded.

Cardiopulmonary exercise tests

CPET were performed using a metabolic cart (Quark-CPET, COSMED, Rome, Italy) and expired gas analysis was measured breath by breath. Other monitoring was similar to the ISWT with the addition of with real-time cardiac monitoring with 12 lead electrocardiography (Quark C12x, COSMED).

Incremental treadmill test

Participants performed a CPET on a trackmaster treadmill (Full Vision INC., Newton, KS, USA). Six minutes of resting measurements were followed by 3 min of slow walking on a flat surface as a warm up before the incremental protocol commenced. The incremental protocol used a simultaneous change in speed and grade every minute to achieve a linear response in oxygen uptake (VO₂),¹⁰ aiming to elicit a test duration between 8 and 12 min. The protocol was individualized for each participant by using their fast walking speed and their predicted peak power.¹¹

The presence and assessment of exercise-induced bronchoconstriction (EIB) was assessed during the CPET according to the American Thoracic Society (ATS) guidelines¹² by measuring FEV₁ before and repeatedly after at 5, 10, 15, 20 and 30 min post exercise. EIB severity was defined by the percentage decrease in FEV₁ from baseline: mild ≥10% to <25%; moderate ≥25% to <50% and severe if ≥50% as per ATS guidelines on EIB.

Incremental cycle ergometry

Participants performed a CPET on an electrically braked cycle ergometer (Lode Corival, Lode B.V., Groningen, The Netherlands). Six minutes of resting measurements were followed by 3 min of unloaded pedalling at 60 revolutions per minute (RPM) before the ramp protocol commenced. The rate of work increase was calculated according to the predicted maximum work rate for each participant, accounting for their height, age and weight¹¹ with the aim to elicit exhaustion within 8–12 min.¹³

Statistical analysis

The normality of the data was assessed using the Kolmogorov-Smirnov test. The difference between parametric data was assessed using repeated measures analysis of variance (ANOVA). Friedman's test was used to assess the difference between groups for non-parametric data. For post hoc analysis, Bonferroni adjustment was used to correct for multiple testing. The intraclass correlation coefficients were determined between the three shuttle walk tests. The coefficient of repeatability, and the precision, for the difference between the second and third ISWT distance were calculated using the methods described by Bland and Altman.¹⁴ Heteroscedasticity was demonstrated by performing linear regression on the absolute difference




Figure 1 Study design. ICE, incremental cycle ergometer; ISWT, incremental shuttle walk test; ITM, incremental treadmill.

between the second and third ISWT distance versus the average ISWT distance.¹⁵ Pearson's correlation coefficient was used to assess the validity between the third ISWT distance and the $\text{VO}_{2\text{pk}}$ derived from both ITM and ICE. All P -values of <0.05 were considered statistically significant.

RESULTS

A total of 61 patients were recruited and 50 patients completed all three visits. Three patients were withdrawn from the study, two due to hospital admission for an asthma exacerbation and one due to a new diagnosis of sarcoma. Eight patients dropped out of the study for personal reasons. In total, 50 patients completed both ITM and ISWT and 49 patients completed ICE; one patient was not able to perform the CPET on the cycle ergometer due to limited knee extension from previous bilateral knee replacements. The baseline characteristics of the participants (Table 1) were similar between the completers and non-completers except for FEV_1 which was higher for the non-completers.

Repeatability of ISWT

The mean ISWT distance for the three ISWT were 400 (156), 418 (142) and 438 (157) m, respectively ($P = 0.001$) (Table 2), with an intraclass correlation of 0.963 ($P < 0.001$). Overall, there was a significant difference between the distance walked for ISWT1 and ISWT3 (mean difference (95% CI): -38 (-68 to -8), $P = 0.008$), and between ISWT2 and ISWT3 (mean difference (95% CI): -20 [-34 to -6], $P = 0.003$). The most common reason for terminating the tests on all three occasions was breathlessness (Table 2).

Figure 2 represents the coefficient of repeatability (80 m) of the distance walked between the second and third ISWT. However, the variation of the difference

between the second and third ISWT ($R^2 = 0.273$, $P < 0.01$) was dependent on the magnitude of the average ISWT distance, that is the increase in the third ISWT distance was greater in patients with a higher average ISWT distance which is termed heteroscedasticity.

Validity of the ISWT distance

Table 3 shows the peak physiological values for the CPET derived from the ITM and ICE. Our study population reached more than 80% of their predicted maximum heart rate (82% on ICE and 89% on ITM). Of the 50 patients, 22 developed mild to moderate EIB (no participant developed severe EIB).

The ISWT distance showed a strong correlation with $\text{VO}_{2\text{pk}}$ on ITM ($r = 0.74$, $P < 0.001$) and ICE ($r = 0.75$, $P < 0.001$) (Fig. 3).

DISCUSSION

Among patients with severe asthma, a small increase in ISWT distance occurs on repeated testing which is more pronounced in patients with better exercise capacity. We demonstrated that there was a strong correlation between the ISWT distance and $\text{VO}_{2\text{pk}}$ derived from either an ICE test or an ITM test. The ISWT distance has validity as a measure of exercise capacity in patients with severe asthma but is not interchangeable with laboratory exercise testing methods.

The mean ISWT distance is repeatable after a familiarization test in other pulmonary and cardiac diseases.¹⁶ According to our data, patients with severe asthma improve their ISWT distance despite having an initial familiarization test. The within-group difference between the second and the third shuttle walk tests was small (approximately 20 m). However, in clinical practice to be certain, a true change in ISWT distance has occurred within an individual post intervention, a distance of >80 m would need to be achieved (i.e. more than the coefficient of repeatability). This is slightly higher than the distance of 60 m reported for patients with either COPD or chronic heart failure (CHF).¹⁷

There could be some potential factors contributing to improvement in ISWT distance on repeated testing in patients with severe asthma. By comparing the peak values on the third ISWT, ICE and ITM for heart rate, BP and perceived breathlessness and exertion (Table 3), we can conclude that patients did not achieve their maximal values and performed submaximally on their initial shuttle walk test. As a result, the improvement in the shuttle walk test could have been as a result of patients pushing themselves slightly harder at each test. Low self-confidence and fear of exacerbating asthma symptoms among this group of patients could have contributed to the submaximal performance on the shuttle walk tests which slightly improved at each repeated testing,¹⁸ perhaps as patients were reassured by how they felt following the initial test. Assessment of maximal exercise capacity via a laboratory-based test such as CPET elicited a maximal exercise performance compared to the field-based ISWT. As our study population perceived themselves as

Table 1 Baseline characteristics of participants

Patient characteristics	Completers ($n = 50$)	Non-completers ($n = 11$)
Age (years)	54 (13)	51 (16)
Female, n (%)	33 (66)	5 (45)
MRC [†]	2 (2–3)	2 (2–3)
BMI (kg/m^2)	32 (6)	34 (8)
FEV_1 (L)	1.9 (0.8)*	2.3 (0.4)
FEV_1 (%)	69 (20)	71 (15)
% FEV_1/FVC	68 (11)	75 (12)
ICS dose ($\mu\text{g}/\text{day}$)	1586 (326)	1455 (311)
Maintenance oral steroid, n (%)	28 (56)	22 (44)
Oral steroid dose (mg)	8 (4)	9 (4)
Atopic, n (%)	34 (68)	8 (73)

* $P < 0.05$.

Data presented as mean (SD).

[†]Median (IQR), percentage or frequency as indicated.

BMI, body mass index; FEV_1 , forced expiratory volume in 1 s; FVC, forced vital capacity; ICS, inhaled corticosteroid; IQR, interquartile range; MRC, Medical Research Council dyspnoea scale; n , number.

Table 2 Results of the ISWT

	ISWT1	ISWT2	ISWT3	P-value
Distance (m)	400 (156)	418 (142)	438 (157)	†‡
Borg breathlessness scale§				
Before	0.5 (0–1)	0 (0–0.5)	0.5 (0–0.5)	†,‡
After	3 (3–4)	3 (2–4)	3 (3–5)	†
Borg perceived exertion scale§				
Pre-test	6 (6–7)	6 (6–7)	6 (6–7)	†
Post-test	13 (11–15)	13 (11–14)	13 (12–15)	†
Heart rate				
Pre-test	88 (13)	82 (11)	82 (13)	‡,‡
Post-test	123 (21)	120 (18)	124 (18)	†
Systolic BP				
Pre-test	128 (15)	128 (16)	131 (17)	N/A
Post-test	144 (22)	146 (21)	141 (21)	N/A
Diastolic BP				
Pre-test (mm Hg)	86 (11)	82 (10)	85 (11)	‡,‡
Post-test (mm Hg)	87 (19)	88(14)	88 (14)	N/A
SpO ₂				
Pre-test	95 (2)%	96 (2)%	96 (2)%	†,‡
Post-test	93 (3)%	93 (3)%	93 (3)%	N/A
Limiting symptom				
SOB (n)	20	20	24	N/A
Leg fatigue (n)	11	12	9	N/A
SOB and leg fatigue (n)	2	5	8	N/A
General fatigue (n)	14	12	8	N/A
Others (n)	3	1	1	N/A

Data presented as mean (SD).

† $P < 0.05$ between ISWT2 and ISWT3.

‡ $P < 0.05$ between ISWT1 and ISWT3.

§Median (IQR).

‡ $P < 0.05$ between ISWT1 and ISWT2.

BP, blood pressure; IQR, interquartile range; ISWT, incremental shuttle walk test; N/A, not applicable; SOB, shortness of breath; SpO₂, oxygen saturation.




Figure 2 Repeatability of ISWT among patients with severe asthma. The solid line represents the mean difference between ISWT3 and ISWT2, the dashed lines represent the repeatability coefficient and the dotted lines represent the precision of the coefficient of repeatability. ISWT, incremental shuttle walk test.

being unfit with low confidence to exercise, the reassuring presence of the monitoring devices used in laboratory-based testing may have contributed to their better performance on CPET.

As expected, the mean (SD) ISWT distance was higher in our patients with severe asthma compared to the studies among COPD and CHF patients with moderate to severe disease (302 (133) and 380 (190) m accordingly).^{4,19} However, the average ISWT distance was lower in our study population compared to adults with obstructive sleep apnoea (OSA) with obesity, cystic fibrosis (CF) and the healthy population reported in other studies (580 (207), 754 (362) and 733 (183), respectively).^{20–22} The protocol used for ISWT in the OSA and CF studies differed from other studies in that patients were allowed to run as the speed on the ISWT increased. We adhered to the original protocol for performing ISWT as described by Singh *et al.*,⁴ where ISWT was validated with walking only. This could explain why patients with CF had a slightly higher ISWT distance compared to healthy individuals and may also explain the better performance on ISWT among patients with OSA and CF compared to the patients with severe asthma in our study. Additionally, the lower ISWT distance among our patients could indicate that walking on the flat surface was not enough of a stimulus to provoke a maximal exercise test from them.

Table 3 Comparison between the results of the cardiopulmonary exercise tests and the ISWT

	ITM	ICE	ISWT	P-value
VO _{2pk} (mL/min)	1969 (586)	1528 (500)	N/A	†
VO _{2pk} (mL/min/kg)	23 (6)	18 (5)	N/A	†
VCO _{2pk} (mL/min)	1974 (721)	1606 (563)	N/A	†
Peak RR (breath/min)	37 (8)	33 (8)	N/A	†
Peak HR (beat/min)	145 (19)	137 (21)	124 (18)	†, ‡, §
% Predicted HR	89 (10)	82 (10)	75 (11)	†, ‡, §
VE _{max} (L/min)	64 (23)	53 (21)	N/A	†
%MVV (L/min)	94 (25)	80 (22)	N/A	†
RER at VO _{2pk}	1.0 (0.1)	1.03 (0.1)	N/A	†
Systolic BP (mm Hg)	155 (23)	154 (26)	141 (21)	‡, §
Diastolic BP (mm Hg)	83 (15)	80 (14)	88 (14)	§
SpO ₂	97 (3)%	98 (2)%	93 (3)%	†, ‡, §
Borg breathlessness [¶]	5 (4–8)	5 (4–7)	3 (3–5)	‡, §
Perceived exertion [¶]	15 (13–17)	17 (15–19)	13 (12–15)	†, ‡, §

Data presented as mean (SD).

† $P < 0.05$ between ITM and ICE.

‡ $P < 0.05$ between ITM and ISWT.

§ $P < 0.05$ between ICE and ISWT.

¶ Median (IQR).

BP, blood pressure; HR, heart rate; ICE, incremental cycle ergometer; IQR, interquartile range; ISWT, incremental shuttle walk test; ITM, incremental treadmill; MVV, maximum voluntary ventilation; N/A, not applicable; RER, respiratory exchange ratio; RR, respiratory rate; SpO₂, oxygen saturation; VCO_{2pk}, peak carbon dioxide elimination; VE_{max}, maximum minute ventilation; VO_{2pk}, peak oxygen uptake.




Figure 3 A comparison between VO_{2pk} measured on ITM (A) and ICE (B) with the ISWT distance. The solid line represents the best line of fit with dashed lines representing 95% CI. ICE, incremental cycle ergometer; ISWT, incremental shuttle walk test; ITM, incremental treadmill; VO₂, oxygen uptake; VO_{2pk}, peak oxygen uptake.

Other factors that could have limited the value of the ISWT as a maximal exercise test in this group of patients include the effects of their elevated BMI on both agility and, hip and knee joints, which may have made the turning points uncomfortable and slower to complete. Whilst patients with OSA had a similar mean BMI (at 33 kg/m²) compared to our patients with severe asthma, patients with OSA were allowed to run during the ISWT which may have compensated for the effects of slowing at the turn points.

Patients with severe asthma often have persisting eosinophilic airway inflammation and issues with non-adherence to medication, and as a result may be prone

to develop EIB. EIB usually occurs 5–10 min after the cessation of modest periods of high-intensity exercise and a short period of hyperpnoea and resolves spontaneously within 30–90 min.¹² After resolution of EIB, patients enter a refractory period for up to 2–4 h and if they engage in another bout of exercise within the refractory period, they may not develop EIB.²³ Of the 50 patients, 22 developed EIB (13 patients mild and 9 patients moderate EIB) after the ITM, which supports the possibility of EIB post the ISWT among some of these participants. This refractory period could potentially account for some of the improvement in the third ISWT distance that was performed at least 30 min after

the second ISWT supported by our data as the statistically significant difference occurred after the third ISWT.

There were some limitations of this study including (i) portable expiratory gas analysis was not performed during the ISWT to assess whether there was the same linear increase in oxygen uptake and $\text{VO}_{2\text{pk}}$ as achieved in the ITM and ICE. However, in clinical practice, the outcome measure for ISWT is the distance covered by the participant and the results from our study showed that there was strong correlation between the ISWT distance and $\text{VO}_{2\text{pk}}$ on both ITM and ICE but the tests are not interchangeable. (ii) We cannot exclude the effect of refractory period post EIB on the improvement in the third ISWT distance as we did not perform spirometry after the second and third shuttle walk tests. (iii) A specific sample size calculation was not performed, from our sample size of 49 participants the precision of the coefficient repeatability was ± 20 m, so we are 95% confident that the coefficient of repeatability of the ISWT lies between 60 and 100 m (Fig. 2). A larger sample size would only refine the estimate within this range which is unlikely to aid further interpretation within an individual in clinical practice. (iv) The familiarization ISWT was performed in the same visit as a CPET which may have led to a submaximal performance if they had not fully recovered after the CPET despite the 30-min rest.

In conclusion, there was a small increase in ISWT distance on repeated testing which needs to be considered when used as an outcome measure for non-randomized clinical trials. In clinical practice, the coefficient of repeatability and the presence of heteroscedasticity need to be considered when assessing whether a true change has occurred from an intervention within an individual patient. The ISWT distance has validity compared to $\text{VO}_{2\text{pk}}$ both on ITM and ICE, but they are not interchangeable in patients with severe asthma.

Acknowledgements

We would like to thank L. Houchen-Wolloff, S. Edwards, B. Popat, T. Harvey-Dunstan and L. Haynes for their assistance in conducting the tests. This study was funded by NIHR Research for Patient Benefit grant PB-PG-0712-28063. Dr R.A.E. holds an NIHR clinical scientist fellowship CS-2016-16-020. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

Abbreviations: ATS, American Thoracic Society; BP, blood pressure; CF, cystic fibrosis; CHF, chronic heart failure; CPET, cardiopulmonary exercise test; EIB, exercise-induced bronchoconstriction; FEV_1 , forced expiratory volume in 1 s; HR, heart rate; ICE, incremental cycle ergometer; IQR, interquartile range; ISWT, incremental shuttle walk test; ITM, incremental treadmill; OSA, obstructive sleep apnoea; SOB, shortness of breath; SpO_2 , oxygen saturation; $\text{VO}_{2\text{pk}}$, peak oxygen uptake.

REFERENCES

- Disabella V, Sherman C. Exercise for asthma patients: little risk, big rewards. *Phys. Sportsmed.* 1998; **26**: 75–84.
- Westermann H, Choi TN, Briggs WM, Charlson ME, Mancuso CA. Obesity and exercise habits of asthmatic patients. *Ann. Allergy Asthma Immunol.* 2008; **101**: 488–94.
- Vermeulen F, Garcia G, Ninane V, Laveneziana P. Activity limitation and exertional dyspnea in adult asthmatic patients: what do we know? *Respir. Med.* 2016; **117**: 122–30.
- Singh SJ, Morgan MD, Scott S, Walters D, Hardman AE. Development of a shuttle walking test of disability in patients with chronic airways obstruction. *Thorax* 1992; **47**: 1019–24.
- Newall C, Stockley RA, Hill SL. Exercise training and inspiratory muscle training in patients with bronchiectasis. *Thorax* 2005; **60**: 943–8.
- Evans RA, Singh SJ, Collier R, Loke I, Steiner MC, Morgan MD. Generic, symptom based, exercise rehabilitation; integrating patients with COPD and heart failure. *Respir. Med.* 2010; **104**: 1473–81.
- Bradley J, Howard J, Wallace E, Elborn S. Validity of a modified shuttle test in adult cystic fibrosis. *Thorax* 1999; **54**: 437–9.
- British Thoracic Society/Scottish Intercollegiate Guideline Network Guideline on Asthma 2014: SIGN 141. British guideline on the management of asthma. <https://www.brit-thoracic.org.uk/document-library/clinical-information/asthma/btssign-asthma-guideline-2014/>. Accessed: March 2019.
- Borg GA. Psychophysical bases of perceived exertion. *Med. Sci. Sports Exerc.* 1982; **14**: 377–81.
- Porszasz J, Casaburi R, Somfay A, Woodhouse LJ, Whipp BJ. A treadmill ramp protocol using simultaneous changes in speed and grade. *Med. Sci. Sports Exerc.* 2003; **35**: 1596–603.
- Jones NL. *Clinical Exercise Testing*, 4th edn. Amsterdam, Elsevier Health Services, 1997.
- Parsons JP, Hallstrand TS, Mastronarde JG, Kaminsky DA, Rundell KW, Hull JH, Storms WW, Weiler JM, Cheek FM, Wilson KC *et al.*; American Thoracic Society Subcommittee on Exercise-Induced Bronchoconstriction. An official American Thoracic Society clinical practice guideline: exercise-induced bronchoconstriction. *Am. J. Respir. Crit. Care Med.* 2013; **187**: 1016–27.
- Ross RM. ATS/ACCP statement on cardiopulmonary exercise testing. *Am. J. Respir. Crit. Care Med.* 2003; **167**: 1451 author reply 1451.
- Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. *Lancet* 1986; **1**: 307–10.
- Pollock MA, Jefferson SG, Kane JW, Lomax K, MacKinnon G, Winnard CB. Method comparison – a different approach. *Ann. Clin. Biochem.* 1992; **29**(Pt 5): 556–60.
- Parreira VF, Janaudis-Ferreira T, Evans RA, Mathur S, Goldstein RS, Brooks D. Measurement properties of the incremental shuttle walk test. A systematic review. *Chest* 2014; **145**: 1357–69.
- Harvey-Dunstan TC, Singh SJ, Steiner MC, Morgan MD, Evans RA. P39 A comparison of the repeatability and responsiveness of field and laboratory incremental exercise tests between COPD and chronic heart failure. *Thorax* 2013; **68**: A92–3.
- Apps LD, Hewitt S, Green R, Bradding P, Murphy A, Martin N, Singh S, Hudson N, Evans R. Exercise perspectives & rehabilitation: challenges in severe asthma. *Eur. Respir. J.* 2015; **46**(Suppl. 59): PA3722.
- Green DJ, Watts K, Rankin S, Wong P, O'Driscoll JG. A comparison of the shuttle and 6 minute walking tests with measured peak oxygen consumption in patients with heart failure. *J. Sci. Med. Sport* 2001; **4**: 292–300.
- Evans RA, Dolmage TE, Robles PG, Goldstein RS, Brooks D. Do field walking tests produce similar cardiopulmonary demands to an incremental treadmill test in obese individuals with treated OSA? *Chest* 2014; **146**: 81–7.
- Bradley J, Howard J, Wallace E, Elborn S. Reliability, repeatability, and sensitivity of the modified shuttle test in adult cystic fibrosis. *Chest* 2000; **117**: 1666–71.
- Harrison SL, Greening NJ, Houchen-Wolloff L, Bankart J, Morgan MD, Steiner MC, Singh SJ. Age-specific normal values for the incremental shuttle walk test in a healthy British population. *J. Cardiopulm. Rehabil. Prev.* 2013; **33**: 309–13.
- Belcher NG, O'Hickey S, Arm JP, Lee TH. Pathogenetic mechanisms of exercise-induced asthma and the refractory period. *N. Engl. J. Allergy Proc.* 1988; **9**: 199–201.